Influence of artificial intelligence in modern pharmaceutical formulation and drug development

被引:14
作者
Ali, Kazi Asraf [1 ]
Mohin, S. K. [1 ]
Mondal, Puja [1 ]
Goswami, Susmita [1 ]
Choudhuri, Sabyasachi [1 ]
Ghosh, Soumya [1 ]
机构
[1] Maulana Abul Kalam Azad Univ Technol, Dept Pharmaceut Technol, Haringhata 741249, W Bengal, India
关键词
Artificial intelligence; Machine learning; Nano medicine; Nano robots; Pharmaceutical formulation; Drug development; DELIVERY SYSTEMS SEDDS; NEURAL-NETWORKS; PARTICLE-SIZE; PREDICTIVE CONTROL; SOLID DISPERSIONS; GENETIC ALGORITHM; RESPONSE-SURFACE; PHASE-BEHAVIOR; ORAL DELIVERY; RELEASE;
D O I
10.1186/s43094-024-00625-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Artificial intelligence (AI) revolutionized the formulation and development of modern pharmaceuticals. With the help of AI, researchers can now optimize drug design, develop formulations, and streamline clinical trials in a much accurate and efficient way. Drug development might be greatly expedited and time-consuming procedure; however, with the help of AI this are significantly reduced.Main body of abstract The main advantages of AI in pharmaceutical formulation are its capacity to analyse vast amounts of data and spot patterns and connections that human researchers would miss. Various tools and technologies, such as ANN, fuzzy logic, neuro-fuzzy logic, and genetic algorithm are used for analysing the date, of which ANN is popular and mostly used. AI enables the discovery of novel pharmacological targets and the creation of more potent medications. AI may also be used to improve medication formulations by forecasting the solubility, stability, and bioavailability of drug candidates, increasing the likelihood that clinical trials will be successful. AI is also applied in designing clinical trials, reducing the time and cost of the process by identifying patient populations that are most likely to benefit from the treatment. Additionally, AI can monitor patients during clinical trials, detecting real-time adverse effects and adjusting dosages to improve patient outcomes.Main body of abstract The main advantages of AI in pharmaceutical formulation are its capacity to analyse vast amounts of data and spot patterns and connections that human researchers would miss. Various tools and technologies, such as ANN, fuzzy logic, neuro-fuzzy logic, and genetic algorithm are used for analysing the date, of which ANN is popular and mostly used. AI enables the discovery of novel pharmacological targets and the creation of more potent medications. AI may also be used to improve medication formulations by forecasting the solubility, stability, and bioavailability of drug candidates, increasing the likelihood that clinical trials will be successful. AI is also applied in designing clinical trials, reducing the time and cost of the process by identifying patient populations that are most likely to benefit from the treatment. Additionally, AI can monitor patients during clinical trials, detecting real-time adverse effects and adjusting dosages to improve patient outcomes.Conclusion AI is a potent pharmaceutical formulation and development tool, allowing researchers to analyse vast amounts of data, optimize drug formulations, and streamline clinical trials. As technology develops, experts anticipate that AI will increasingly show a crucial part in drug development, enabling faster, more efficient, and more effective treatments for various diseases.
引用
收藏
页数:15
相关论文
共 112 条
[1]   Prediction of a stable microemulsion formulation for the oral delivery of a combination of antitubercular drugs using ANN methodology [J].
Agatonovic-Kustrin, S ;
Glass, BD ;
Wisch, MH ;
Alany, RG .
PHARMACEUTICAL RESEARCH, 2003, 20 (11) :1760-1765
[2]   Role of genetic algorithms and artificial neural networks in predicting the phase behavior of colloidal delivery systems [J].
Agatonovic-Kustrin, S ;
Alany, RG .
PHARMACEUTICAL RESEARCH, 2001, 18 (07) :1049-1055
[3]   A Review of the Role of Artificial Intelligence in Healthcare [J].
Al Kuwaiti, Ahmed ;
Nazer, Khalid ;
Al-Reedy, Abdullah ;
Al-Shehri, Shaher ;
Al-Muhanna, Afnan ;
Subbarayalu, Arun Vijay ;
Al Muhanna, Dhoha ;
Al-Muhanna, Fahad A. .
JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (06)
[4]   Determination of factors controlling the particle size in nanoemulsions using Artificial Neural Networks [J].
Amani, Amir ;
York, Peter ;
Chrystyn, Henry ;
Clark, Brian J. ;
Do, Duong Q. .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 35 (1-2) :42-51
[5]   Preparation of biodegradable nanoparticles of tri-block PLA-PEG-PLA copolymer and determination of factors controlling the particle size using artificial neural network [J].
Asadi, H. ;
Rostamizadeh, K. ;
Salari, D. ;
Hamidi, M. .
JOURNAL OF MICROENCAPSULATION, 2011, 28 (05) :406-416
[6]  
Bagwe RP, 2001, CRIT REV THER DRUG, V18, P77, DOI 10.1615/CritRevTherDrugCarrierSyst.v18.i1.20
[7]   Size, Loading Efficiency, and Cytotoxicity of Albumin-Loaded Chitosan Nanoparticles: An Artificial Neural Networks Study [J].
Baharifar, Hadi ;
Amani, Amir .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 106 (01) :411-417
[8]   Artificial neural networks (ANNs) and partial least squares (PLS) regression in the quantitative analysis of cocrystal formulations by Raman and ATR-FTIR spectroscopy [J].
Barmpalexis, P. ;
Karagianni, A. ;
Nikolakakis, I. ;
Kachrimanis, K. .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2018, 158 :214-224
[9]   Development of PVP/PEG mixtures as appropriate carriers for the preparation of drug solid dispersions by melt mixing technique and optimization of dissolution using artificial neural networks [J].
Barmpalexis, Panagiotis ;
Koutsidis, Ioannis ;
Karavas, Evangelos ;
Louka, Dimitra ;
Papadimitriou, Sofia A. ;
Bikiaris, Dimitrios N. .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2013, 85 (03) :1219-1231
[10]   Solid dispersions in the development of a nimodipine floating tablet formulation and optimization by artificial neural networks and genetic programming [J].
Barmpalexis, Panagiotis ;
Kachrimanis, Kyriakos ;
Georgarakis, Emanouil .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2011, 77 (01) :122-131